Judy Chou, AltruBio CEO
May 21, 2024 08:00 AM EDT
Financing
Startups

Al­tru­Bio se­cures $225M for an up­dat­ed ver­sion of its ul­cer­a­tive col­i­tis drug

Kyle LaHucik

Senior Reporter

Bay Area and Taipei biotech Al­tru­Bio has raised $225 mil­lion in a Se­ries B to move for­ward its ex­per­i­men­tal drug for ul­cer­a­tive col­i­tis and oth­er …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times